GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Capex-to-Operating-Income

CellSource Co (TSE:4880) Capex-to-Operating-Income : 0.00 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

CellSource Co's Capital Expenditure for the three months ended in Jan. 2024 was 円0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was 円205.86 Mil.

Hence, CellSource Co's Capex-to-Operating-Income for the three months ended in Jan. 2024 was 0.00.


CellSource Co Capex-to-Operating-Income Historical Data

The historical data trend for CellSource Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Capex-to-Operating-Income Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.16 0.08 0.06 0.06 0.29

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CellSource Co's Capex-to-Operating-Income

For the Biotechnology subindustry, CellSource Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where CellSource Co's Capex-to-Operating-Income falls into.



CellSource Co Capex-to-Operating-Income Calculation

CellSource Co's Capex-to-Operating-Income for the fiscal year that ended in Oct. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-359.002) / 1221.503
=0.29

CellSource Co's Capex-to-Operating-Income for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 205.861
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellSource Co  (TSE:4880) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


CellSource Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of CellSource Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines